China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - While China reported a slowdown of its economic growth in the second quarter - 10.3 percent compared to 11.9 percent in the same year-ago quarter - many economists feared China was close to overheating, but the life science industry in China is still hot to global investors, and Chinese generics companies are evolving to become more integrated and innovative, according to speakers from the FT China Healthcare and Life Science Summit held in Shanghai July 13